Login to Your Account

'High Hurdle' for Future Trials

FDA Welcomes Yervoy Aboard; Will Nod Calm Melanoma Seas?

By Becky Jungbauer

Monday, April 4, 2011
The approval of Bristol-Myers Squibb Co.'s Yervoy (ipilimumab) is the first for the metastatic melanoma space in more than a decade. The New York-based pharma's CTLA-4-blocking antibody also was the first therapy to demonstrate a significant improvement in overall survival, and analysts are estimating the drug will bring in sales of $1 billion in the U.S. alone. (See BioWorld Today, March 28, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription